Groupe Solactis Signs Management Buy-Out for Vitaloa/Solactis Research Program

26 July 2013 --- Groupe SOLACTIS SAS, which aims to become a leading French biotech company specializing in nutritional ingredients, for human and animal health, today officially signed the MBO (Management Buy-Out) agreement of the Vitaloa/Solactis Research & Innovation Programme, previously run by SOLVAY SA.

Created from the research activities of SOLVAY SA on food ingredients and digestive health, based on renewable materials and chemistry, Group Solactis SAS is a biotech company focused on nutritional innovations dedicated to specific research partnerships with food groups, academic laboratories, as well as with other biotech firms in targeted health nutritional areas such as digestive health, transit regulation and immunity. These are the most advanced markets of food products bearing health benefits, through the world.

Groupe SOLACTIS SAS will draw on its unique expertise in the field of intestinal flora and prebiotic actions to offer solutions throughout the entire new food product development cycle, from the identification of new targeted health benefits up to the discovery of new end-products.

In order to achieve its objectives, Groupe SOLACTIS SAS now has at its disposal the dossiers which enabled to obtain health claims on prebiotic (South Korea) and transit (Europe Union) for galactofructose (or lactulose), application patents, unique dry forms specially adapted to the food industry, clinical studies and numerous tests in diversified food matrices. For its promotion, Groupe SOLACTIS will be able to build on the growing awareness of its Solactis brand for human nutrition, and Vitaloa brand for animal feed.

Pascal RONFARD, founder and President of Groupe SOLACTIS SAS, said: “This MBO signed with SOLVAY is the culmination of an ambitious project to create a player which principal characteristics is to be rooted on business basics: clear regulatory authorizations, positive development studies, first inclusions in end-products…: we deliver! This is certainly the inheritage of sound R&D development plans, driven in a pragmatic approach. Groupe SOLACTIS SAS will capitalize on the human nutrition and animal feed rapidly growing markets, to implement significant partnerships and contracts with food and feed groups, in its areas of specialization: digestive health, transit regulation and immunity. Through this MBO, Groupe SOLACTIS SAS has acquired all the necessary assets to become a new player in human nutrition and animal feed.”